LEXINGTON, Ky.--(BUSINESS WIRE)--AllTranz, Inc., a specialty pharmaceutical company focused on developing drugs to treat a variety of neurologic and inflammatory disorders, today announced that it has been awarded a $4 million research grant from the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), to advance the company’s transdermal tetrahydrocannabinol (THC) patch for the treatment of marijuana dependence and withdrawal. The grant was awarded through the American Recovery and Reinvestment Act of 2009 (ARRA) and will directly support preclinical development and a planned Phase I clinical study.
